Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Nuance Acquires China Rights to Osteoarthritis Pain Drug in $100 Million Deal

publication date: Feb 9, 2021

Shanghai Nuance Pharma in-licensed Greater China rights to a late-stage candidate for osteoarthritis pain from Toronto's Antibe Therapeutics in a $100 million agreement. Otenaproxesul is similar to naproxen, but it is designed to avoid naproxen's gastrointestinal side effects. Nuance identifies and in-licenses China rights to therapies that have achieved best-in-class, human proof-of-concept status. Nuance will pay $20 million upfront and $80 million in milestones, plus royalties. More details....

Stock Symbols: (TSX: ATE; OTCQB: ATBPF)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.